GENE ONLINE|News &
Opinion
Blog

Eisai
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
Revolutionary Wristband Sensor Technology Predicts Alzheimer’s Risk
2024-01-04
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
FDA Granted Eisai and Biogen’s New Alzheimer’s Drug a Traditional Approval, Making Medicare Coverage Possible
2023-07-11
GeneOnline’s Weekly News Highlights: July 3-7
2023-07-10
Merck, Eisai’s Keytruda-Lenvima Combo Fails in Melanoma and Colorectal Cancer Trials
2023-04-10
Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval
2023-01-09
Eisai Touts Lenvima Efficacy In Thyroid Cancer Study
2022-10-24
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Merck and Eisai Come Up Short in the Clinic with Liver Cancer Combination Therapy
2022-08-04
Eisai and Biogen’s New Alzheimer’s Drug to Receive FDA Decision by January
2022-07-06
Eisai to File Another Biogen-Partnered Alzheimer’s Drug After Confidence Hit
2022-05-10
EMA Rejects Marketing Authorization Application of Aduhelm
2021-12-20
FDA Grants Breakthrough Status to Two Experimental Alzheimer’s Drugs While Pushback Over Aduhelm’s Approval Still Rages On
2021-06-25
1 2 3
LATEST
Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital
2024-12-10
The Future of Generative AI for New Drug Development and Precision Medicine
2024-12-09
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
AI, Smart Tech, and ICT to Unite the Global Biotech and Healthcare Industries in 2025
2024-12-06
Core8 Group to Establish Vietnam’s First Comprehensive Biotechnology Incubator
2024-12-05
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
2024-12-05
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
EVENT
Scroll to Top